Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Status:
Terminated
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability, recommended phase 2 dose (RP2D), and to characterize PK of TAK-228 administered once daily or once weekly to East Asian participants with advanced nonhematological malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.